Cantor Fitzgerald Downgrades Salix Pharmaceuticals (SLXP) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
UBS Downgrades Salix Pharmaceuticals (SLXP) to Neutral
February 24, 2015 7:22 AM ESTUBS downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Neutral.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $155.76 yesterday.
... MoreValeant Pharma (VRX) to Acquire Salix Pharma (SLXP) in $14.5B Deal
February 22, 2015 4:29 PM ESTValeant Pharma (NYSE: VRX) and Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Boards of Directors of both companies.
Salix Pharmaceuticals is a widely recognized gastrointestinal market leader with a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a strong near- term pipeline of... More
Valeant Pharma (VRX) Nears Deal for Salix Pharma (SLXP) - CNBC's Faber
February 20, 2015 9:46 AM EST(Updated - February 20, 2015 9:55 AM EST)
Valeant Pharma (NYSE: VRX) is near a deal to acquire Salix Pharma (NASDAQ: SLXP), CNBC's David Faber reported Friday.
Notably, rumors of a Salix Pharm takeover have been around... More
